# CLDND2

## Overview
CLDND2 is a gene that encodes the protein claudin domain containing 2, which is a member of the claudin family involved in the formation of tight junctions in cell membranes. These tight junctions are crucial for maintaining cell polarity and regulating paracellular transport, thereby ensuring the integrity of epithelial and endothelial barriers. The CLDND2 protein is characterized by its transmembrane domains, typically featuring three transmembrane helices, and is primarily localized in the cell membrane where it contributes to barrier functions and cellular signaling pathways (Attwood2020Classification; Heinemann2019Structural). The gene has been implicated in various physiological and pathological processes, including its potential role in the pathogenesis of Parkinson's disease and drug-resistant epilepsy, highlighting its significance in maintaining tissue integrity and its potential as a biomarker in disease contexts (Gao2024Multiomics; Han2021Analysis).

## Structure
CLDND2, or claudin domain containing 2, is a protein that is part of the claudin family, which plays a role in forming tight junctions in cell membranes. The protein is characterized by the presence of the PMP-22/EMP/MP20/Claudin family Pfam domain, which is associated with diverse functions (Attwood2020Classification). Proteins in this family typically have four transmembrane helices, but CLDND2 is predicted to have three transmembrane helices (3TMs), with the first N-terminal helix identified as a signal peptide (Attwood2020Classification). This prediction aligns with data from the human protein atlas, which uses a majority decision method to determine the presence of signal peptides and transmembrane regions (Attwood2020Classification).

The primary structure of CLDND2 includes amino acid sequences that form these transmembrane domains. While specific details on the secondary, tertiary, and quaternary structures of CLDND2 are not provided, proteins in the claudin family often exhibit structural motifs such as alpha helices and beta sheets, which contribute to their three-dimensional conformation and functional assembly in tight junctions (Heinemann2019Structural). The protein may undergo post-translational modifications, such as phosphorylation, which can affect its function and localization.

## Function
CLDND2 (claudin domain containing 2) encodes a protein that plays a crucial role in the formation and maintenance of tight junctions in epithelial and endothelial cells. These tight junctions are essential for maintaining cell polarity and regulating paracellular transport, which is the movement of substances across an epithelium by passing through the intercellular space between the cells. The CLDND2 protein is typically active in the cell membrane, where it contributes to the barrier functions and cellular signaling pathways that are vital for maintaining the integrity of tissues and organs (Gao2024Multiomics).

In the context of Parkinson's disease, CLDND2 has been identified as a down-regulated gene in peripheral blood leukocytes of cynomolgus monkeys treated with MPTP, a neurotoxin used to model Parkinson's disease. This down-regulation suggests a potential role in maintaining the integrity of blood-brain and gut barriers, which may be compromised in the disease. The study highlights CLDND2 as a hub gene in gene-gene interactive networks, indicating its potential importance in the pathogenesis of Parkinson's disease (Gao2024Multiomics). However, the specific function of CLDND2 in healthy human cells is not extensively detailed in the available literature.

## Clinical Significance
The CLDND2 gene has been implicated in several diseases and conditions due to alterations in its expression levels. In Parkinson's disease (PD), the downregulation of CLDND2 in cynomolgus monkeys suggests a potential role in the disruption of the blood-brain barrier (BBB) and neuroinflammation. This disruption may allow neurotoxic substances to enter the brain, contributing to neuronal damage and neurodegeneration associated with PD (Gao2024Multiomics). The study highlights CLDND2 as a candidate biomarker for PD, indicating its involvement in maintaining BBB integrity and neuroprotection.

In the context of drug-resistant epilepsy, CLDND2 was identified as a potential resistance gene for carbamazepine (CBZ). The expression of CLDND2 was generally lower in drug-resistant epilepsy cases compared to controls, suggesting its role in drug tolerance and resistance mechanisms (Han2021Analysis).

In bladder cancer, CLDND2 expression was found to be relatively lower in patients, indicating a lesser association with the disease compared to other genes studied. This suggests that while CLDND2 may not be a primary driver of bladder cancer, its expression changes could still be relevant in the context of cancer biology (Shi2019Screen).


## References


[1. (Shi2019Screen) Jing-wen Shi and Ying Huang. Screen and classify genes on bladder cancer associated with metastasis. Gene Reports, 16:100430, September 2019. URL: http://dx.doi.org/10.1016/j.genrep.2019.100430, doi:10.1016/j.genrep.2019.100430. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.genrep.2019.100430)

[2. (Gao2024Multiomics) Jiang-Mei Gao, Shou-Yue Xia, Geoff Hide, Bi-Hai Li, Yi-Yan Liu, Zhi-Yuan Wei, Xiao-Ji Zhuang, Qing Yan, Yun Wang, Wei Yang, Jian-Huan Chen, and Jun-Hua Rao. Multiomics of parkinsonism cynomolgus monkeys highlights significance of metabolites in interaction between host and microbiota. npj Biofilms and Microbiomes, July 2024. URL: http://dx.doi.org/10.1038/s41522-024-00535-3, doi:10.1038/s41522-024-00535-3. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41522-024-00535-3)

[3. (Attwood2020Classification) Misty M. Attwood and Helgi B. Schi√∂th. Classification of trispanins: a diverse group of proteins that function in membrane synthesis and transport mechanisms. Frontiers in Cell and Developmental Biology, January 2020. URL: http://dx.doi.org/10.3389/fcell.2019.00386, doi:10.3389/fcell.2019.00386. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2019.00386)

[4. (Heinemann2019Structural) Udo Heinemann and Anja Schuetz. Structural features of tight-junction proteins. International Journal of Molecular Sciences, 20(23):6020, November 2019. URL: http://dx.doi.org/10.3390/ijms20236020, doi:10.3390/ijms20236020. This article has 114 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms20236020)

[5. (Han2021Analysis) Tenghui Han, Zhenyu Wu, Jun Zhu, Yao Kou, Jipeng Li, and Yanchun Deng. Analysis and construction of a molecular diagnosis model of drug-resistant epilepsy based on bioinformatics. Frontiers in Molecular Biosciences, November 2021. URL: http://dx.doi.org/10.3389/fmolb.2021.683032, doi:10.3389/fmolb.2021.683032. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2021.683032)